SCHEMBL5147963

SCHEMBL5147963

CC(C)n1nc(-c2nc(NCc3ccccn3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.43
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HCRTR1 O43613 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
PDE5A O76074 2/20 0.39
SUMO3 P55854 1/20 0.38
SUMO2 P61956 1/20 0.38
SUMO1 P63165 1/20 0.38
MAPT P10636 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
NPR1 P16066 1/20 0.37
ATAD2 Q6PL18 1/20 0.37
KCNH2 Q12809 3/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482611 0.93 HIF1A (0.38) HIF1AKDM4EALDH1A1MEN1KMT2A
SCHEMBL5149090 0.91 HIF1A (0.45) HIF1AALDH1A1ADORA2AADORA1
SCHEMBL5149160 0.88 HIF1A (0.45) HIF1AKDM4EALDH1A1MEN1KMT2A
SCHEMBL5149144 0.88 LDHA (0.39) HIF1AKDM4EMAPTADORA1TSHR
SCHEMBL6133960 0.84 ADORA2A (0.47) HIF1AKDM4EALDH1A1MEN1KMT2A
SCHEMBL5147952 0.83 KDM4E (0.42) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL5149189 0.82 SYK (0.42) ADORA2A
SCHEMBL5150823 0.82 KDM4E (0.39) HIF1AKDM4EALDH1A1POLBGAA
SCHEMBL5149119 0.82 GSK3B (0.39) HIF1AKDM4EALDH1A1PDE5AADORA2A
SCHEMBL5150946 0.82 TLR8 (0.44) KDM4EALDH1A1POLBMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 HIF1A 416/4885KDM4E 3683/4885ALDH1A1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.